All In Biotech

Drug Trial Radar · NCT01732757

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

Last checked: Nov 20, 2026Latest source record: Jan 14, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 157 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

157

Actual

Start

Nov 2012

Primary completion

Dec 2012

Study completion Dec 2012

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 26, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.

Conditions

  • Conjunctivitis, Allergic

Interventions

  • Alcaftadine 0.25%Drug

    One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.

  • Olopatadine 0.2%Drug

    One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.

  • dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%Drug

    One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular Itching Evaluated by the Subject 3 Minutes Post Challenge on Day 0Time frame: Day 0 at 3 Minutes Post Challenge

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.